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COMMENT & RESPONSE
Are Antiplatelet Agents Beneficial in Prevention
of Infective Endocarditis?
To the Editor Recently, Lancellotti et al1 suggested that ticagre-
lor protected the participants of the Platelet Inhibition and Pa-
tient Outcomes study from infectious adverse events2 via an
unforeseen antimicrobial activity. Ticagrelor was found bac-
tericidal in vitro against gram-positive pathogens, including
Staphylococcus aureus, but not gram-negative bacteria. More-
over, ticagrelor interfered with S aureus biofilm formation in
vitro and in a mouse model of patch infection. However, in vitro
bactericidal concentrations of ticagrelor were 10-fold to 40-
fold greater than reachable in vivo serum levels. The authors
speculated that platelets could have delivered the drug at the
infected site. While this could be measured, it is in contradic-
tion with the ticagrelor antiplatelet activity, which should curb
platelet deposition at inflamed sites.
Here, we suggest a few alternative mechanisms that could
explain ticagrelor-induced modulation of S aureus infectiv-
ity. First, platelet inhibitors interfering with the glycoprotein
IIb/IIIa activation, such as aspirin, can modulate S aureus global
regulatory networks that determine the expression of viru-
lence factors.3 Salicylic acid altered the expression of the
S aureus alternative σ factor B, which in turn alters the expres-
sion of global regulator genes accessory gene regulator (agr)
and staphylococcal accessory regulator (sar). agr is a quorum-
sensing regulator that decreases the expression of adhesins
(including fibrinogen-binding and fibronectin-binding pro-
teins) and increases the expression of toxins (including hemo-
lysins) at high bacterial densities. agr also indirectly pro-
motes biofilm formation. sar is a reciprocal DNA-binding
regulator stimulating adhesin expression and inhibiting agr.
Thus, σ factor B alteration simultaneously alters S aureus ex-
pression of surface adhesins and secretes toxins, decreasing
the ability of S aureus to colonize damaged tissues and form
necrotic abscesses and biofilm.
Second, S aureus binds to fibrinogen. Staphylococcal-
bound fibrinogen undergoes a conformational change that in-
duces binding of fibrinogen to platelet receptor glycoprotein
IIb/IIIa, resulting in platelet activation. Activated platelets bind
to endothelial-attached von Willebrand factor and trigger lo-
cal coagulation, which provides a sheath protecting staphy-
lococci from attack by phagocytes. Not to say that alteration
of expression of membrane-bound muropeptide resistance fac-
tor, a positively charged protein that can impair the activity
of membrane-active daptomycin, could explain the interest-
ing ticagrelor-daptomycin synergism.
All in all, the potential pleiotropic mechanisms behind
ticagrelor-mediated protection against infection further high-
light the importance of the work by Lancellotti et al.1 It rein-
forces other recent studies showing that platelet inhibitors can
protect infection-related mortality4 as well as experimental en-
docarditis in rodents.5 This is one more argument to seri-
ously consider platelet inhibition as a potent strategy to pre-
vent infection in selected at-risk patients.
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In Reply Heying et al proposed some mechanisms that could
underlie the in vivo bactericidal activity of the antiplatelet drug
ticagrelor against gram-positive bacteria.1 They speculate that
these mechanisms would be common to those already ob-
served in the presence of other platelet inhibitors, in particu-
lar in the context of Staphylococcus aureus bloodstream infec-
tion or experimental endocarditis. On the one hand, salicylic
acid alters the expression of adhesins or toxins by S aureus,
thereby potentially decreasing its ability to colonize dam-
aged tissues, and acetylsalicylic conferred some protection to
patients against S aureus bloodstream infection. On the other
hand, by interfering with S aureus–triggered glycoprotein IIb/
IIIa activation, platelet inhibitors targeting this platelet path-
way might also prevent local fibrin generation that hampers
bacteria eradication by immune cells. In view of the paucity
of treatments against septicaemiae or infective endocarditis,
more research is needed to determine whether antiplatelet
agents could prove beneficial to patients with cardiovascular
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disease at risk of such bacterial infection. However, whether
the in vivo bactericidal effect of ticagrelor is related to its an-
tiplatelet activity and/or to its ability to inhibit platelet-
leucocyte interactions2 or whether it directly targets bacteria
survival mechanisms is currently unknown.
Our hypothesis that platelets could serve as ticagrelor car-
riers and produce local bactericidal concentration is based both
on the reversibility of ticagrelor binding to platelet P2Y123 and
on experimental studies showing that platelets are recruited to
sites of bacterial infection similarly as immune cells. Platelets
indeed express receptors for chemokines, such as CCR1, CCR3,
CCR4, and CXCR4, which recognize the 4 classes of chemo-
kines (C, CC, CXC, and CX3C) generated at sites of infection, as
well as pattern recognition receptors, which detect various bac-
terial pathogen-associated molecular patterns.4 To the best of
our knowledge, no studies have ever investigated whether ti-
cagrelor inhibits platelet chemotaxis or whether it interferes with
direct or indirect platelet binding to bacteria. Platelet recep-
tors that have been involved in platelet-bacteria interactions in-
clude glycoprotein IIb/IIIa, glycoprotein Ibα, and the Fcγ recep-
tor IIa receptor for immunoglobulin G. Moreover, it has been
reported that platelets exert antistaphylococcal responses by re-
leasing microbicidal proteins or kinocidins, a process that is in-
hibited by the direct P2Y12 inhibitor cangrelor but not by the
antagonism of the thromboxane A2 and cyclooxygenase 1
pathway.5 This implies that targeting platelet P2Y12 might
not always be beneficial. Furthermore, currently available an-
tiplatelet agents may have different or opposite effects on
bacterial infection.
Thus, as indicated by Heying et al, the pleiotropic prop-
erties of ticagrelor are likely to be responsible for its in vivo bac-
tericidal activity. The use of appropriate animal models is re-
quired to compare platelet inhibitors targeting P2Y12 or those
targeting distinct platelet pathways in bacterial infection. Mod-
els with human-like pharmacokinetics should be preferred to
guarantee data transferability to humans.
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Substantial Differences Between Cohorts
of Patients Hospitalized With Heart Failure
in Canada and the United States
To the Editor Samsky et al1 compared the trends in readmis-
sions for patients hospitalized with heart failure in Canada and
the United States, but substantial differences between the co-
horts from the 2 countries call into question the validity of their
conclusion. The cohort from the United States included pa-
tients who were younger than 65 years and enrolled in Medi-
care owing to disability or end-stage renal disease—a distinct
group of younger patients who accounted for about 10% of the
cohort. The Canadian cohort also included patients who were
younger than 65 years but who, unlike their counterparts in
the United States, were in general healthier than the older pa-
tients and accounted for about 15% of the cohort. The read-
mission rate for the younger group from Canada was more than
3% lower than that of the older patients in the cohort (15.6%
vs 18.7%), while the readmission rate for the younger pa-
tients in the United States was about 2.5% higher than that of
the older patients in the cohort (22.1% vs 19.6%). Although the
authors conducted a sensitivity analysis restricted to pa-
tients 65 years and older, it was limited to the association of
length of stay with 30-day readmissions. No sensitivity analy-
sis results were reported on trends of readmission, which is
the focus of the article.
The article reports a large difference in in-hospital mor-
tality between the patients in Canada (9.9%) and the United
States (3.8%), although eFigure 1B in the Supplement1 surpris-
ingly indicates an even lower in-hospital mortality (less than
1%) for patients in the United States. Lack of mortality infor-
mation in the postdischarge 30-day period creates additional
concern about rate comparisons between the countries—a con-
cern that cannot be alleviated by the finding of 0.9% postdis-
charge 30-day mortality from a study cited by the authors2 that
was based on Medicare Advantage patients admitted for all
causes. The postdischarge 30-day mortality rate for Medicare
fee-for-service patients with heart failure is known to be much
higher, at approximately 8%.3
Lastly, the rationale for restricting data to the period from
2006 to 2015 for segmented regression analysis is unclear. Al-
though 2005 data did not comprise a complete year, they did
span 3 full fiscal quarters, which were the units of segmented
regression analysis. The Figure1 outlining quarterly trends over
the years did not present data points after 2013, and it is not
clear whether quarterly data from 2014 and 2015 were in-
cluded for the segmented regression analysis, which would
have implications for the results.
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